SCHEMBL3526550

SCHEMBL3526550

Nc1ncc(I)c2scc(Br)c12

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 1/20 0.39
HTT P42858 2/20 0.35
KMT2A Q03164 1/20 0.35
BTK Q06187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525389 0.78 EPHB4 (0.39) EPHB4HTTKMT2ABTK
SCHEMBL13708272 0.78 LMNA (0.31) EPHB4
SCHEMBL31129022 0.74 HTT (0.42) EPHB4HTTKMT2A
SCHEMBL3531482 0.74 EPHB4 (0.36) EPHB4HTTKMT2ABTK
SCHEMBL3531469 0.74 EPHB4 (0.36) EPHB4HTTKMT2ABTK
SCHEMBL3530457 0.74 BTK (0.54) EPHB4BTK
SCHEMBL3377004 0.74 KDR (0.54) EPHB4BTK
SCHEMBL31128943 0.73 TSHR (0.37) EPHB4KMT2A
SCHEMBL3534163 0.71 BTK (0.55) EPHB4BTK
SCHEMBL3529709 0.71 BTK (0.59) EPHB4BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-7592352-B2 Substituted thieno and furo-pyridines SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592352-B2 Substituted thieno and furo-pyridines SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592352-B2 Substituted thieno and furo-pyridines SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
CN-101336244-A 9-membered heterobicyclic compounds useful as protein kinase inhibitors ABBOTT LAB (US) 2008-12-31 CN disclosed
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-10-16 US disclosed
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-10-16 US disclosed
WO-2007067781-A2 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES ABBOTT LABORATORIES (US) 2007-06-14 WO disclosed
WO-2007056625-A2 THIENOPYRIDINE B-RAF KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-18 WO disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
EP-1620094-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-01 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 US disclosed
WO-2004100947-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 EPHB4 877/4885HTT 3422/4885KMT2A 1067/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK EPHB4 896/4885HTT 4072/4885KMT2A 1305/4885
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors BRAF, RAF1, ARAF EPHB4 651/4885HTT 3441/4885KMT2A 1552/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK EPHB4 896/4885HTT 4072/4885KMT2A 1305/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK EPHB4 896/4885HTT 4072/4885KMT2A 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.